Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ulcer: later-stage trial registry
10 of 14 indexed Ulcer trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 10 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Ulcer: 14 US clinical trials tracked, 10 recruiting.
Ulcer is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Tiger Biosciences, running 2 of these trials.
Enrollment posture brief
Registry condition ulcer
OPEN 10 | RECR 71% | LATE 5 | EARLY 1 | RANK #1230 | SPON 2
Volume-matched condition peers
Nearest open-share peer: ACL Tear (71% recruiting · 7 trials)
Ulcer lists 10 open slots (71% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ulcer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ulcer is recruiting above its size-band peers.
10 of 14 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Ulcer trials is spread across many organizations.
Tiger Biosciences accounts for 2 of 14 trials (14.3%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Ulcer enrolment sits around 119 participants.
Median target enrolment is 119 among the 14 trials that report a genuine target (sentinel values excluded). 5 of those (35.7%) plan for fewer than 100 participants.
-
Ulcer research is mostly interventional.
13 interventional and 1 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
BioLab Holdings
NCT07089602
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers
Tiger Biosciences
NCT06999590
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
Sequence LifeScience
NCT07086443
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.
Tiger Biosciences
NCT06826339
IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers
ConvaTec
NCT06616844
Onyx™ Liquid Embolic IDE Clinical Study
Medtronic Endovascular
NCT06742801
Total Contact Soft Cast in Diabetic Foot Ulcers
University of Minnesota
NCT04210089
Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment
Christopher C. Thompson, MD, MSc
NCT06543316
Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.
Applied Biologics
NCT07360418
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
BioLab Holdings
NCT07364630
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Cumberland Pharmaceuticals
NCT00061633
NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing
Larry Lavery
NCT02519621
Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System
Capso Vision
NCT04573959
Feasibility Study of a Novel Device for Chronic Wounds
Stanford University
NCT00660049
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Ulcer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ulcer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ulcer page
14 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Ulcer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Tiger Biosciences sponsors the most Ulcer trials on record, review their full trial history before evaluating a specific study. See Tiger Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ulcer condition card totals 14 registered trials; most-linked intervention Membrane Wrap-Hydro™ DFU; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.